Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced that CEO Ivor Elrifi will present at the Bio International Convention on June 18, in Boston.
His talk will highlight recent clinical findings on intranasal foralumab, the company’s lead candidate and the first fully human anti-CD3 monoclonal antibody delivered intranasally.
This approach aims to treat neuroinflammatory and neurodegenerative diseases by activating regulatory T cells while minimizing systemic immune suppression.
Phase 2 trials are underway in SPMS and planned for early Alzheimer’s.